Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Intangibles data on file, last reported at $174.0 million in Q1 2026.

• Intangibles for Q1 2026 came in at $174.0 million, down 1.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $174.0 million (down 1.43% YoY), and the FY2025 annual result was $176.0 million, down 1.12% from the prior year.
• Intangibles fell to $174.0 million in Q1 2026 per RARE's latest filing, from $176.0 million in the prior quarter.
• Over five years, Intangibles peaked at $178.0 million in Q4 2024 and troughed at $157.3 million in Q3 2023.
• A 5-year average of $166.3 million and a median of $165.0 million in 2024 frame the typical range for Intangibles.
• The sharpest annual moves came in 2022 and 2026: Intangibles grew 22.42% in 2022, then slipped 1.43% in 2026.
• A 5-year view of Intangibles shows it stood at $160.1 million in 2022, then advanced by 3.85% to $166.3 million in 2023, then rose by 7.05% to $178.0 million in 2024, then dropped by 1.12% to $176.0 million in 2025, then declined by 1.14% to $174.0 million in 2026.
• Business Quant data shows RARE's Intangibles at $174.0 million in Q1 2026, $176.0 million in Q4 2025, and $172.9 million in Q3 2025.